BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 15, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Frova regulatory update

Vernalis disclosed in its 1H11 earnings that Russia approved frovatriptan to treat migraine. Menarini Group (Florence, Italy) has rights...

Read the full 82 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >